227 related articles for article (PubMed ID: 19229288)
1. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.
Osada T; Yang XY; Hartman ZC; Glass O; Hodges BL; Niedzwiecki D; Morse MA; Lyerly HK; Amalfitano A; Clay TM
Cancer Gene Ther; 2009 Sep; 16(9):673-82. PubMed ID: 19229288
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA.
Gabitzsch ES; Xu Y; Balint JP; Hartman ZC; Lyerly HK; Jones FR
Cancer Immunol Immunother; 2010 Jul; 59(7):1131-5. PubMed ID: 20361185
[TBL] [Abstract][Full Text] [Related]
3. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
Gabitzsch ES; Tsang KY; Palena C; David JM; Fantini M; Kwilas A; Rice AE; Latchman Y; Hodge JW; Gulley JL; Madan RA; Heery CR; Balint JP; Jones FR; Schlom J
Oncotarget; 2015 Oct; 6(31):31344-59. PubMed ID: 26374823
[TBL] [Abstract][Full Text] [Related]
4. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.
Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Gayle RB; Amalfitano A; Jones FR
Immunol Lett; 2009 Jan; 122(1):44-51. PubMed ID: 19073216
[TBL] [Abstract][Full Text] [Related]
5. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.
Morse MA; Chaudhry A; Gabitzsch ES; Hobeika AC; Osada T; Clay TM; Amalfitano A; Burnett BK; Devi GR; Hsu DS; Xu Y; Balcaitis S; Dua R; Nguyen S; Balint JP; Jones FR; Lyerly HK
Cancer Immunol Immunother; 2013 Aug; 62(8):1293-301. PubMed ID: 23624851
[TBL] [Abstract][Full Text] [Related]
6. An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors.
Catalucci D; Sporeno E; Cirillo A; Ciliberto G; Nicosia A; Colloca S
J Virol; 2005 May; 79(10):6400-9. PubMed ID: 15858023
[TBL] [Abstract][Full Text] [Related]
7. Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine.
Gabitzsch ES; Xu Y; Balint JP; Balcaitis S; Sanders-Beer B; Jones FR
Vaccine; 2011 Oct; 29(45):8101-7. PubMed ID: 21864618
[TBL] [Abstract][Full Text] [Related]
8. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted.
Amalfitano A; Hauser MA; Hu H; Serra D; Begy CR; Chamberlain JS
J Virol; 1998 Feb; 72(2):926-33. PubMed ID: 9444984
[TBL] [Abstract][Full Text] [Related]
9. Decreased Vector Gene Expression from E2b Gene-Deleted Adenovirus Serotype 5 Vaccines Intensifies Proinflammatory Immune Responses.
Quiroga D; Aldhamen YA; Godbehere S; Harding L; Amalfitano A
Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28381403
[TBL] [Abstract][Full Text] [Related]
10. Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3.
Gorziglia MI; Lapcevich C; Roy S; Kang Q; Kadan M; Wu V; Pechan P; Kaleko M
J Virol; 1999 Jul; 73(7):6048-55. PubMed ID: 10364357
[TBL] [Abstract][Full Text] [Related]
11. An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice.
Gabitzsch ES; Xu Y; Balcaitis S; Balint JP; Jones FR
Cancer Gene Ther; 2011 May; 18(5):326-35. PubMed ID: 21233857
[TBL] [Abstract][Full Text] [Related]
12. Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity.
Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Amalfitano A; Jones FR
Vaccine; 2009 Oct; 27(46):6394-8. PubMed ID: 19559110
[TBL] [Abstract][Full Text] [Related]
13. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted.
Lusky M; Christ M; Rittner K; Dieterle A; Dreyer D; Mourot B; Schultz H; Stoeckel F; Pavirani A; Mehtali M
J Virol; 1998 Mar; 72(3):2022-32. PubMed ID: 9499056
[TBL] [Abstract][Full Text] [Related]
15. Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors.
Everett RS; Hodges BL; Ding EY; Xu F; Serra D; Amalfitano A
Hum Gene Ther; 2003 Dec; 14(18):1715-26. PubMed ID: 14670123
[TBL] [Abstract][Full Text] [Related]
16. Conditional repression of the E2 transcription unit in E1-E3-deleted adenovirus vectors is correlated with a strong reduction in viral DNA replication and late gene expression in vitro.
Rittner K; Schultz H; Pavirani A; Mehtali M
J Virol; 1997 Apr; 71(4):3307-11. PubMed ID: 9060700
[TBL] [Abstract][Full Text] [Related]
17. Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer.
Balint JP; Gabitzsch ES; Rice A; Latchman Y; Xu Y; Messerschmidt GL; Chaudhry A; Morse MA; Jones FR
Cancer Immunol Immunother; 2015 Aug; 64(8):977-87. PubMed ID: 25956394
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
[TBL] [Abstract][Full Text] [Related]
19. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted.
Zhou H; O'Neal W; Morral N; Beaudet AL
J Virol; 1996 Oct; 70(10):7030-8. PubMed ID: 8794347
[TBL] [Abstract][Full Text] [Related]
20. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
